Akebia Therapeutics (AKBA) Net Income towards Common Stockholders (2013 - 2026)

Akebia Therapeutics (AKBA) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 248.13% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at -$20.5 million (up 54.73% YoY), while the FY2025 annual figure was -$5.3 million, up 92.3% from the prior year.
• Net Income towards Common Stockholders improved to -$9.1 million in Q1 2026 per AKBA's latest filing, from -$12.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $29.4 million in Q2 2022 and bottomed at -$63.5 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$13.4 million across 5 years, with a median of -$11.2 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 135.46% — and 2024, when it tumbled 3814.01%.
• Akebia Therapeutics' Net Income towards Common Stockholders stood at -$4.1 million in 2022, then soared by 114.89% to $614000.0 in 2023, then sank by 3814.01% to -$22.8 million in 2024, then jumped by 46.31% to -$12.2 million in 2025, then grew by 26.05% to -$9.1 million in 2026.
• Business Quant data shows AKBA's Net Income towards Common Stockholders at -$9.1 million in Q1 2026, -$12.2 million in Q4 2025, and $540000.0 in Q3 2025.